Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M |
| Total Depreciation and Amortization | 415.00K | 515.00K | 501.00K | 563.00K | 558.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.90M | 1.39M | 1.40M | -169.00K | 1.19M |
| Change in Net Operating Assets | -8.85M | 8.23M | -2.18M | 34.00K | 5.25M |
| Cash from Operations | -43.32M | -31.95M | -44.92M | -37.06M | -27.49M |
| Capital Expenditure | -2.00K | -4.00K | -- | -532.00K | -102.00K |
| Sale of Property, Plant, and Equipment | 70.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.49M | 29.17M | 5.58M | 29.75M | 778.00K |
| Cash from Investing | 22.56M | 29.17M | 5.58M | 29.22M | 676.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -120.00K | -262.00K | -341.00K | -247.00K | -242.00K |
| Issuance of Common Stock | 1.65M | 0.00 | 3.00K | 32.00K | 90.00K |
| Repurchase of Common Stock | -43.00K | -51.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -336.00K | -76.00K | 0.00 | 0.00 |
| Cash from Financing | 1.49M | -649.00K | -414.00K | -215.00K | -152.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.28M | -3.43M | -39.75M | -8.05M | -26.97M |